2023

15 November 2023 – Results of Annual General Meeting

15 November 2023 – Annual General Meeting 2023 Presentation

31 October 2023 – Appendix 4C & Quarterly Report

17 October 2023 – Notice of Meeting, Proxy and Voting Guide

16 October 2023 – Antisense to Participate in upcoming Industry Conferences

9 October 2023 – Launch of Share Sale Facility for Unmarketable Parcels

28 September 2023 – New Data Published, and Patent Filed, for ATL1102 in ‘Long COVID’

26 September 2023 – New Preclinical Data for ATL1102 in Limb Girdle Muscular Dystrophy R2

28 August 2023 – Corporate Presentation_August 2023

25 August 2023 – Appendix 4E and Annual Report – 30 June 2023 

21 August 2023 – Antisense Share Purchase Plan raises $3.26M

7 August 2023 – Commencement of Chief Executive Officer

26 July 2023 – Positive new DMD Combination Therapy Data in mdx mice

20 July 2023 – Intention to launch Share Purchase Plan

18 July 2023 – Institutional Placement and proposed Share Purchase Plan

27 June 2023 – MHRA Approval Received to Conduct Phase IIb Trial in the UK for ATL1102 in DMD

8 June 2023 – First Patient Dosed in AL1102 Phase IIb DMD Trial

6 June 2023 – Shareholder Newsletter

8 May 2023 –    Chief Executive Officer and Managing Director Appointment

26 April 2023 – ATL1102 Phase IIb DMD trial – Bulgarian approval received with UK and Australian approval process advancing

17 April 2023 – Quarterly Activities Report & Appendix 4C

14 March 2023 – Dosing Commenced in the ATL1102 toxicology study

14 February 2023 – First approval received for ATL1102 Phase IIb DMD clinical trial

13 February 2023 – Dosing commenced in Limb Girdle Muscular Dystrophy R2 animal study

1 February 2023 – Positive outcomes in DMD combination therapy animal study

25 January 2023 – Quarterly Activities Report & Appendix 4C

2022

19 December 2022 – Clinical Trial Application submitted for ATL1102 Phase IIb DMD trial conduct in Europe

17th November 2022 –  Annual General Meeting 2022 Presentation

                                                    Annual General Meeting results

16th November 2022 – Antisense Therapeutics CEO announces retirement

14th November 2022 – ATL1102 toxicology study to support clinical program in the US

19th October 2022 – Notice of Annual General Meeting & Proxy Form

                                                2022 Annual Report

14 October 2022 – Receipt of further R&D Tax Incentive Payment

                                           Non-Executive Director retirement

5 October 2022 – Company Appointment – Chief Commercial Officer

12 September 2022 – Dosing commenced in DMD combination therapy study

7 September 2022 – ATL1102 for DMD: Revised Clinical Development Plans

31 August 2022 – Appendix 4E & Full Statutory Accounts

19 August 2022  – Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets

28 July 2022 – Investor Presentation

27 July 2022 – Quarterly Activities/Appendix 4C

13 July 2022 – ATL1102 for DMD Clinical Trial Application Submitted in Europe

28 June 2022 – Proteomics and disease marker identification in DMD Webinar

24 June 2022 – ANP Presentation – PPMD 2022 Annual Conference

20 June 2022 – New Indication for ATL1102 for Limb Girdle Muscular Dystrophy R2

15 June 2022 – Presentation at CNS Summit

27 May 2022 – Investor Presentation

29 April 2022 – Bonus Option Issue Letter to Shareholders

28 April 2022 – Quarterly Update & Appendix 4C_31 Mar 22

14 April 2022 – Receipt of RD Tax Incentive payment

12 April 2022 – Bonus Option Offer

14 March 2022 – Significant modulation of two bone morphogenetic proteins supports potential of ATL1102 for improving bone density in DMD

1 March 2022 – Poster Presentation at 2022 MDA Clinical & Scientific Conference